Home>Topics>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Isis earns milestone payment from Biogen

    Headlines

    Thu, 21 Aug 2014

    Pharmaceuticals ( ISIS -3.1% ) discloses that it earned an $18M milestone payment from development partner Biogen Idec ( BIIB -1.1% ) by virtue of dosing the first infant in the ENDEAR Phase 3 clinical trial evaluating ISIS-SMNrx as

  2. New Morningstar Analyst Report for Perrigo Co PLC

    Stock Reports

    Tue, 19 Aug 2014

    expect relatively flat royalty payments from Tysabri due to emerging competition from oral multiple sclerosis drugs like Biogen Idec ’s Tecfidera. We currently don’t forecast material future cash flows for an expanded indication of Tysabri in

  3. Biogen's MS therapeutic cleared for sale in U.S.

    Headlines

    Sat, 16 Aug 2014

    The FDA approves Biogen Idec 's (NASDAQ: BIIB ) Plegridy ( peginterferon beta-1a ) for the treatment of patients with relapsing forms of multiple sclerosis (MS). It is

  4. UPDATE 1- Biogen wins U.S. approval of long acting multiple sclerosis drug

    Headlines

    Fri, 15 Aug 2014

    NEW YORK, AUG 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc 's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older...

  5. FDA approves Biogen Idec's multiple sclerosis drug

    Headlines

    Fri, 15 Aug 2014

    Aug 15 (Reuters) - U.S. health regulators on Friday approved Biogen Idec Inc 's Plegridy, a long-acting multiple sclerosis drug that the company expects will eventually replace its older big-selling...

  6. New Morningstar Analyst Report for Alnylam Pharmaceuticals Inc

    Stock Reports

    Fri, 8 Aug 2014

    directors, one of whom--Phillip Sharp--won the Nobel Prize in 1993 for his work with DNA and also cofounded Biogen (now Biogen Idec ). Although Sharp and Maraganore clearly lack independence from management, we think Alnylam's other seven

  7. BioMed Realty Trust's (BMR) Hosts 2014 Investor Day (Transcript)

    Headlines

    Thu, 7 Aug 2014

    Katz – Vice President and Director, Brookings Institution Ed Dondero – Director of Real Estate and Planning at Biogen Idec John Fry – President, Drexel University Presentation Rick Howe [Starts Abruptly] Investor Day 2014, on the 10th

  8. Isis set for milestone payment from Biogen

    Headlines

    Fri, 1 Aug 2014

    infants with spinal muscular atrophy (SMA). This event will trigger an $18M milestone payment from development partner Biogen (NASDAQ: BIIB ). The primary endpoint of the 110-infant study is survival or permanent ventilation. 1 comment!

  9. Momenta Shifts Operations on Generic Copaxone Approval Delay

    Commentary

    Fri, 1 Aug 2014

    in Copaxone sales this quarter, which ultimately reduces the market opportunity for Momenta as new oral drugs, like Biogen Idec ’s Tecfidera, alter the competitive landscape of the multiple sclerosis market. Additionally, Teva has now shifted

  10. New Morningstar Analyst Report for Exelixis Inc

    Stock Reports

    Fri, 1 Aug 2014

    Morrissey (former president of R&D at Exelixis) replaced longtime CEO George Scangos, who left the company to lead Biogen Idec . Morrissey has made his mark by restructuring the company away from its discovery platform model to focus primarily

« Prev12345Next »
Content Partners